<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dulaglutide: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dulaglutide: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Dulaglutide: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="97312" href="/d/html/97312.html" rel="external">see "Dulaglutide: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="140321" href="/d/html/140321.html" rel="external">see "Dulaglutide: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block spa drugH1Div" id="F59011441"><span class="drugH1">Special Alerts</span>
<div class="collapsible">
<span class="collapsible-title">Glucagon-Like Peptide-1 Receptor Agonists Safety Update</span>
<span class="collapsible-date">January 2024</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">The FDA has been evaluating reports of suicidal thoughts or actions in patients treated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs). A preliminary evaluation has not found evidence that the use of these medicines causes suicidal thoughts or actions, but the FDA is continuing to investigate this issue. Patients should not stop taking GLP-1 RAs without consulting their health care provider. Health care providers should monitor for and advise patients using GLP-1 RAs to report new or worsening depression, suicidal thoughts, or any unusual changes in mood or behavior.</p>
<p style="text-indent:0em;">Further information may be found at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fdrug-safety-and-availability%2Fupdate-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-actions-patients-taking-certain-type&amp;token=miTanb%2Bz8Mpo90N4aa9rnBvzPyMcyGMouSYn352zIq27XyRAnm%2BDWunTXNDIRGRVPdvEcJ4t0dBZwKHPsWODdcKNBqg8p81GHTpH2D6qQhfyYSllM0BIXdmigC6Atf7BXgPxeZTU1rPJai25j9dr%2BiXxmVJc5lhSTyKtYrSUSj8%3D&amp;TOPIC_ID=97148" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/update-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-actions-patients-taking-certain-type</a>.</p></div>
</div>
</div>
<div class="block black-box-warn drugH1Div" id="F25944185"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Risk of thyroid C-cell tumors:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">In male and female rats, dulaglutide causes a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure. It is unknown whether dulaglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of dulaglutide-induced rodent thyroid C-cell tumors has not been determined.</p>
<p style="text-indent:-2em;margin-left:2em;">Dulaglutide is contraindicated in patients with a personal or family history of MTC and in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC with use of dulaglutide and inform them of symptoms of thyroid tumors (eg, mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound monitoring is of uncertain value for early detection of MTC in patients treated with dulaglutide.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F26111594"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Trulicity</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871818"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Trulicity</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F25944081"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antidiabetic Agent, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist</li></ul></div>
<div class="block doa drugH1Div" id="F26122239"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-4em;margin-left:4em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical</b>
<b>considerations</b>: May require a dose reduction of insulin and/or insulin secretagogues (sulfonylureas, meglitinides) to avoid hypoglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32022600']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32022600'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2ad35dab-7cea-4ec1-88c5-ab393b3cfc22">Diabetes mellitus, type 2, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes mellitus, type 2, treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> May be used as an adjunctive agent or alternative monotherapy for select patients, including those in whom initial therapy with lifestyle intervention and metformin failed, <b>or</b> who cannot take metformin. May be preferred in patients who have or are at risk for atherosclerotic cardiovascular disease, when weight loss is desired, and/or in patients with an HbA<sub>1c</sub> relatively far from goal (eg, HbA<sub>1c</sub> 9% to 10%) and type 1 diabetes is not likely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.3','lexi-content-ref-31189511','lexi-content-ref-Wexler.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.3','lexi-content-ref-31189511','lexi-content-ref-Wexler.1'])">Ref</a></span>). Due to lack of additive glycemic benefit, avoid concomitant use with a dipeptidyl peptidase-4 inhibitor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30291106']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30291106'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ:</b> Initial: 0.75 mg once weekly; may increase to 1.5 mg once weekly after 4 to 8 weeks if needed to achieve glycemic goals (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Dungan.1','lexi-content-ref-24842985','lexi-content-ref-25912221']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Dungan.1','lexi-content-ref-24842985','lexi-content-ref-25912221'])">Ref</a></span>). If additional glycemic control is needed, may further increase to 3 mg once weekly after at least 4 weeks on the 1.5 mg weekly dose and then to a maximum of 4.5 mg once weekly after at least 4 weeks on the 3 mg weekly dose.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Missed doses:</i> Missed dose should be administered as soon as possible within 3 days; resume usual schedule thereafter. If there are &lt;3 days until next scheduled dose, omit the missed dose and resume administration at the next scheduled weekly dose.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990468"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> Mild to severe impairment: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>). Use caution when initiating or escalating doses; new onset or worsening of existing renal failure has been reported, most commonly in patients experiencing volume depletion from GI losses (eg, vomiting, diarrhea, dehydration).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>): No supplemental dose or dosage adjustment necessary; use with caution due to limited clinical evidence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>): No dosage adjustment necessary; use with caution due to limited clinical evidence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987730"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>
<div class="block doe drugH1Div" id="F26122240"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F57549784"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="140321" href="/d/html/140321.html" rel="external">see "Dulaglutide: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7253bb59-b685-4f43-aa48-4aa83f602807">Diabetes mellitus, type 2; adjunct to diet and exercise</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes mellitus (DM), type 2; adjunct to diet and exercise:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Glucagon-like peptide-1 (GLP-1) receptor agonists may be considered an additional therapeutic option in pediatric patients with type 2 DM who are ≥3 months post-diagnosis with an HbA<sub>1c</sub> of ≥6.5% while on metformin therapy (maximized) in addition to a healthy lifestyle (eg, diet and exercise) with or without insulin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36161685']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36161685'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥10 years and Adolescents &lt;18 years: SUBQ: Initial: 0.75 mg once weekly; if additional glycemic control needed after 4 weeks, may increase to 1.5 mg once weekly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35658022','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35658022','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents ≥18 years: SUBQ: Initial: 0.75 mg once weekly; if additional glycemic control needed after 4 weeks, may increase to 1.5 mg once weekly. If additional glycemic control is needed, may titrate in 1.5 mg increments after at least 4 weeks at current dose up to a maximum weekly dose: 4.5 mg/dose.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F57549795"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥10 years and Adolescents: SUBQ:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mild to severe impairment:</i> No dosage adjustment necessary. Use caution when initiating or escalating doses; new-onset or worsening of existing renal failure has been reported, most commonly in patients experiencing volume depletion from GI losses (eg, vomiting, diarrhea, dehydration).</p></div>
<div class="block dohp drugH1Div" id="F57549796"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>
<div class="block arsc drugH1Div" id="F55634681"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Acute kidney injury</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute kidney injury </b>(AKI), which sometimes requires dialysis, has been reported with dulaglutide and other glucagon-like peptide 1 receptor agonists.<b> Interstitial nephritis</b> has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36385974']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36385974'])">Ref</a></span>). According to the manufacturer, AKI secondary to dulaglutide was seen mostly in patients who had experienced nausea, vomiting, diarrhea, or dehydration. In a post-hoc analysis of multiple clinical trials, dulaglutide was not associated with an increase in adverse effects reflecting potential acute kidney failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27766728']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27766728'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non–dose-related; exact mechanism is unknown. Pre-renal AKI may occur due to dehydration and volume contraction secondary to gastrointestinal symptoms (eg, nausea, vomiting, diarrhea) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26177483']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26177483'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; because the mechanism is thought to be related to volume contraction, timing may be dependent on GI symptoms, initiation or dosage adjustment of concomitant medications, and/or comorbid conditions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26177483']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26177483'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Volume contraction (eg, during periods of severe vomiting or diarrhea) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26177483']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26177483'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Co-administration of medications known to result in kidney injury during episodes of dehydration (eg, drugs that inhibit the renin-angiotensin system) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26177483']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26177483'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting kidney impairment</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Diabetic retinopathy</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">An increased incidence of <b>diabetic retinopathy </b>(DR) was noted during the REWIND study, a clinical trial evaluating the impact of dulaglutide on cardiovascular outcomes in patients with type 2 diabetes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31189511']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31189511'])">Ref</a></span>); the proportion of patients with DR complications was larger among patients with a prior history of DR. In addition, rapid reductions in HbA<sub>1c</sub> are associated with an early worsening of DR (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9682700']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9682700'])">Ref</a></span>); in an analysis of DR complications due to another glucagon-like peptide 1 (GLP-1) receptor agonist (semaglutide), the increased risk of DR was mainly observed in patients with preexisting DR and primarily attributable to the magnitude and rapidity of reduction in HbA<sub>1c</sub> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29178519']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29178519'])">Ref</a></span>). Clinicians should note that this effect has been observed with SUBQ dulaglutide, exenatide, and semaglutide but not other GLP-1 receptor agonists (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33554677','lexi-content-ref-31189511','lexi-content-ref-27633186','lexi-content-ref-27295427']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33554677','lexi-content-ref-31189511','lexi-content-ref-27633186','lexi-content-ref-27295427'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Unknown; in general, worsening of preexisting DR is a known consequence of rapid improvement of hyperglycemia, especially in patients with uncontrolled diabetes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28533296']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28533296'])">Ref</a></span>). Although unlikely, a direct toxic effect or potential angiogenic action of dulaglutide has not been ruled out (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28533296']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28533296'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; clinicians should note that DR is a progressive condition and the onset of DR complications may vary.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting diabetic retinopathy</p>
<p style="text-indent:-2em;margin-left:6em;">• In general, the risk of early worsening of DR is increased when intensive treatment is initiated in patients with long-standing poor glycemic control (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9682700']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9682700'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Gallbladder disease</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gallbladder disease </b>and<b> biliary tract disease</b>, including <b>cholelithiasis,</b> acute <b>cholecystitis</b>, and <b>cholestasis, </b>have been reported with glucagon-like peptide-1 (GLP-1) receptor agonists, including dulaglutide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31189511','lexi-content-ref-35344001','lexi-content-ref-29397376']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31189511','lexi-content-ref-35344001','lexi-content-ref-29397376'])">Ref</a></span>); some have required hospitalization or cholecystectomy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33594405','lexi-content-ref-27478902','lexi-content-ref-35344001','lexi-content-ref-26132939']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33594405','lexi-content-ref-27478902','lexi-content-ref-35344001','lexi-content-ref-26132939'])">Ref</a></span>). Resolution of biliary stones following discontinuation has been documented with other GLP-1 receptor agonists (eg, liraglutide) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25725635']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25725635'])">Ref</a></span>); one patient with dulaglutide-associated cholecystitis successfully continued dulaglutide therapy post-cholecystectomy without recurrent complications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33594405']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33594405'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose- and time-related (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35344001']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35344001'])">Ref</a></span>); not fully understood. Animal studies and in vitro data have demonstrated that GLP-1 enhances the proliferation and functional activity of cholangiocytes, which may result in gallbladder diseases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17631146','lexi-content-ref-18829977']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17631146','lexi-content-ref-18829977'])">Ref</a></span>). Some authors have postulated a change in bile acid production and secretion, suppressed secretion of cholecystokinin, decreased gallbladder emptying, prolonged gallbladder refilling, weight loss, or potentially a combination of these factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30137354','lexi-content-ref-31399438']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30137354','lexi-content-ref-31399438'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied. An increased risk was seen following &gt;26 weeks of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35344001']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35344001'])">Ref</a></span>); one case report, acute cholecystitis developed after 16 months of treatment with dulaglutide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33594405']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33594405'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35344001']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35344001'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Longer duration of treatment (eg, &gt;26 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35344001']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35344001'])">Ref</a></span>))</p>
<p style="text-indent:-2em;margin-left:6em;">• Substantial or rapid weight loss has been associated with an increased risk with other GLP-1 receptor agonists used for weight loss (eg, liraglutide, semaglutide) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35344001']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35344001'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">GI symptoms</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">GI effects, mainly <b>diarrhea</b>, <b>nausea</b>, and <b>vomiting</b>, are the most common adverse reactions associated with glucagon-like peptide 1 (GLP-1) receptor agonists, including dulaglutide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27981757','lexi-content-ref-33199417','lexi-content-ref-25375397']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27981757','lexi-content-ref-33199417','lexi-content-ref-25375397'])">Ref</a></span>). Symptoms may sometimes be severe. <b>Abdominal pain</b>, <b>decreased appetite</b>, and <b>dyspepsia</b> may also occur. GI effects tend to occur during dose escalation and decrease over time (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21975753']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21975753'])">Ref</a></span>); may result in treatment discontinuation.</p>
<p style="text-indent:-2em;margin-left:2em;">In general, long-acting GLP-1 receptor agonists (eg, dulaglutide, once-weekly exenatide, liraglutide, semaglutide) are associated with less nausea and vomiting but more diarrhea when compared to their short-acting counterparts (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27860132']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27860132'])">Ref</a></span>). Dulaglutide may be associated with a lower risk of diarrhea when compared to liraglutide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27860132']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27860132'])">Ref</a></span>). In the SUSTAIN-7 trial comparing once-weekly semaglutide to once-weekly dulaglutide, rates of GI effects were similar for both doses of semaglutide (0.5 mg and 1 mg) and high-dose dulaglutide (1.5 mg) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29397376']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29397376'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; however, the exact mechanism is not fully understood. May be a result of delayed gastric emptying or activation of centers involved in appetite regulation, satiety, and nausea (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26177483']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26177483'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Intermediate; nausea, vomiting, and diarrhea are most common soon after initiation (eg, the first 4 weeks of treatment) and during dose escalation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21975753']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21975753'])">Ref</a></span>). In a post-hoc analysis of 2 clinical trials, GI effects were most common during the first 2 weeks of treatment and the incidence declined rapidly thereafter (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32621083']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32621083'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Dose; generally greater with higher doses</p>
<p style="text-indent:-2em;margin-left:6em;">• In general, rapid titration of GLP-1 receptor agonists is associated with a higher risk of GI symptoms</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Serious, immediate hypersensitivity reactions, including <b>anaphylaxis</b> and <b>angioedema</b>, have been reported with glucagon-like peptide 1 (GLP-1) receptor agonists (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26847401','lexi-content-ref-30350785','lexi-content-ref-25439386','lexi-content-ref-31806579','lexi-content-ref-31296642']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26847401','lexi-content-ref-30350785','lexi-content-ref-25439386','lexi-content-ref-31806579','lexi-content-ref-31296642'])">Ref</a></span>). Exendin-based GLP-1 receptor agonists (eg, exenatide, lixisenatide) are associated with a doubling of reporting odds of anaphylactic reaction compared with human-analogue GLP-1 receptor agonists (eg, liraglutide, dulaglutide, semaglutide) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31806579']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31806579'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Delayed hypersensitivity reactions such as a <b>morbilliform</b>
<b>rash</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33144906']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33144906'])">Ref</a></span>) and <b>injection site reactions</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26177483','lexi-content-ref-26847401']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26177483','lexi-content-ref-26847401'])">Ref</a></span>) have been documented.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non–dose-related; immunologic.</p>
<p style="text-indent:-2em;margin-left:6em;">Immediate hypersensitivity reactions: IgE-antibodies are formed against a drug allergen following initial exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872','lexi-content-ref-30350785','lexi-content-ref-25439386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872','lexi-content-ref-30350785','lexi-content-ref-25439386'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Delayed hypersensitivity reactions: T-cell mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>The risk of immune-mediated adverse effects is low with dulaglutide, despite the formation of neutralizing antibodies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26847401']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26847401'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Immediate hypersensitivity reactions: Rapid; generally occur within 1 hour of administration but may occur up to 6 hours after exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872','lexi-content-ref-31296642']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872','lexi-content-ref-31296642'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Delayed hypersensitivity reactions: Variable; typically maculopapular (morbilliform, exanthematous) eruptions occur 4 to 14 days after drug initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872','lexi-content-ref-26120552']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872','lexi-content-ref-26120552'])">Ref</a></span>), although has been reported up to 5 weeks after starting dulaglutide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33144906']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33144906'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity between GLP-1 receptor agonists is unknown (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32301438','lexi-content-ref-31296642','lexi-content-ref-Steveling.2014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32301438','lexi-content-ref-31296642','lexi-content-ref-Steveling.2014'])">Ref</a></span>). Until further studies are available, dulaglutide should be used with caution in patients with a history of anaphylaxis or angioedema to other GLP-1 receptor agonists. Skin tests have been used in patients with histories of immediate hypersensitivity reactions to GLP-1 receptor agonists (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31296642']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31296642'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Medullary thyroid carcinoma</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">In the early stages of drug development, thyroid C-cell tumors were noted to have developed during animal studies with dulaglutide. It is unknown whether dulaglutide causes thyroid C-cell tumors in humans, as the human relevance of dulaglutide-induced rodent thyroid C-cell tumors has not been determined. According to the manufacturer, one human cases of medullary thyroid carcinoma (MTC) was reported with dulaglutide during clinical trials in a patient with pretreatment calcitonin levels ~8 times the upper limit of normal. In addition, a single case of C-cell hyperplasia with elevated calcitonin levels was noted during the REWIND trial (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31189511']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31189511'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Unknown. Animal studies have shown dose-dependent and treatment duration-dependent harmful effects in rodents but not primates, thereby indicating that proliferative C-cell effects of glucagon-like peptide 1 (GLP-1) receptor agonists may be rodent-specific. Humans have far fewer C-cells than rodents, and expression of the GLP-1 receptor in human C-cells is very low (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20203154']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20203154'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with a personal or family history of MTC or patients with multiple endocrine neoplasia syndrome type 2 (MEN 2) may be at an increased risk</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pancreatitis</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Cases of <b>acute pancreatitis</b> (including hemorrhagic pancreatitis and necrotizing pancreatitis with some fatalities), chronic pancreatitis, and pancreatic adenocarcinoma have been reported with use of incretin-based therapies (eg, dipeptidyl peptidase 4 [DPP-4] inhibitors, glucagon-like peptide 1 [GLP-1] receptor agonists) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23010561','lexi-content-ref-21334333','lexi-content-ref-FDA.2013','lexi-content-ref-24702687','lexi-content-ref-23440284']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23010561','lexi-content-ref-21334333','lexi-content-ref-FDA.2013','lexi-content-ref-24702687','lexi-content-ref-23440284'])">Ref</a></span>). Acute pancreatitis was observed with dulaglutide at rates similar to placebo during the AWARD trial program and the REWIND trial (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31189511','lexi-content-ref-28283565']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31189511','lexi-content-ref-28283565'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Causality has not been firmly established (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24571751']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24571751'])">Ref</a></span>). GLP-1 receptor agonists directly stimulate GLP-1 receptors in pancreatic islet beta cells and exocrine duct cells which may cause an overgrowth of the cells that cover the smaller ducts, thereby resulting in hyperplasia, increased pancreatic weight, duct occlusion, back pressure, and subsequent acute or chronic pancreatic inflammation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27883260','lexi-content-ref-25633664']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27883260','lexi-content-ref-25633664'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Not well characterized.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with a prior history of pancreatitis may be at an increased risk for acute pancreatitis</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with acute pancreatitis due to any cause are at an increased risk for progression to recurrent acute pancreatitis and then to chronic pancreatitis; patients with chronic pancreatitis are at an increased risk for pancreatic cancer (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23622135']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23622135'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Risk factors for pancreatitis due to any cause include, but are not limited to, hypertriglyceridemia, cholelithiasis, alcohol use, and obesity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23622135']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23622135'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F26188918"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults unless otherwise indicated.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypoglycemia (≤77%; highest incidence seen with adjunctive use of insulin or sulfonylureas; severe hypoglycemia: ≤3%; highest incidence seen with adjunctive use of prandial insulin)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (9% to 13%)<span class="lexi-table-link-container"> (<a aria-label="Dulaglutide: Adverse Reaction: Diarrhea table link" class="lexi-table-link" data-table-id="lexi-content-dulaglutide-adverse-reaction-diarrhea" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-dulaglutide-adverse-reaction-diarrhea')">table 1</a>)</span><span class="table-link" style="display:none;">Dulaglutide: Adverse Reaction: Diarrhea</span>, nausea (12% to 21%)<span class="lexi-table-link-container"> (<a aria-label="Dulaglutide: Adverse Reaction: Nausea table link" class="lexi-table-link" data-table-id="lexi-content-dulaglutide-adverse-reaction-nausea" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-dulaglutide-adverse-reaction-nausea')">table 2</a>)</span><span class="table-link" style="display:none;">Dulaglutide: Adverse Reaction: Nausea</span>, vomiting (6% to 13%)<span class="lexi-table-link-container"> (<a aria-label="Dulaglutide: Adverse Reaction: Vomiting table link" class="lexi-table-link" data-table-id="lexi-content-dulaglutide-adverse-reaction-vomiting" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-dulaglutide-adverse-reaction-vomiting')">table 3</a>)</span><span class="table-link" style="display:none;">Dulaglutide: Adverse Reaction: Vomiting</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Dulaglutide: Adverse Reaction: Diarrhea" frame="border" id="lexi-content-dulaglutide-adverse-reaction-diarrhea" rules="all">
<caption style="text-align:center;">
<b>Dulaglutide: Adverse Reaction: Diarrhea</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Dulaglutide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Dulaglutide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1.5 mg once weekly</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">834</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">568</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.75 mg once weekly</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">836</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">568</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Dulaglutide: Adverse Reaction: Nausea" frame="border" id="lexi-content-dulaglutide-adverse-reaction-nausea" rules="all">
<caption style="text-align:center;">
<b>Dulaglutide: Adverse Reaction: Nausea</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Dulaglutide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Dulaglutide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">21%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1.5 mg once weekly</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">834</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">568</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.75 mg once weekly</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">836</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">568</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Dulaglutide: Adverse Reaction: Vomiting" frame="border" id="lexi-content-dulaglutide-adverse-reaction-vomiting" rules="all">
<caption style="text-align:center;">
<b>Dulaglutide: Adverse Reaction: Vomiting</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Dulaglutide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Dulaglutide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1.5 mg once weekly</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">834</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">568</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.75 mg once weekly</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">836</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">568</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: First-degree atrioventricular block (2%), prolongation P-R interval on ECG (3%), sinus tachycardia (6%), sustained tachycardia (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Diabetic retinopathy (2%; more common in patients with history of diabetic retinopathy at baseline)<span class="lexi-table-link-container"> (<a aria-label="Dulaglutide: Adverse Reaction: Diabetic Retinopathy table link" class="lexi-table-link" data-table-id="lexi-content-dulaglutide-adverse-reaction-diabetic-retinopathy" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-dulaglutide-adverse-reaction-diabetic-retinopathy')">table 4</a>)</span><span class="table-link" style="display:none;">Dulaglutide: Adverse Reaction: Diabetic Retinopathy</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Dulaglutide: Adverse Reaction: Diabetic Retinopathy" frame="border" id="lexi-content-dulaglutide-adverse-reaction-diabetic-retinopathy" rules="all">
<caption style="text-align:center;">
<b>Dulaglutide: Adverse Reaction: Diabetic Retinopathy</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Dulaglutide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1.9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1.5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1.5 mg once weekly</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Type 2 diabetes with established cardiovascular disease or multiple cardiovascular risk factors</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1.5 mg once weekly</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Type 2 diabetes with established cardiovascular disease or multiple cardiovascular risk factors</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Patients with a history of diabetic retinopathy at baseline</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1.5 mg once weekly</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Type 2 diabetes with established cardiovascular disease or multiple cardiovascular risk factors</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Patients without a known history of diabetic retinopathy</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distension (2% to 3%), abdominal pain (7% to 9%)<span class="lexi-table-link-container"> (<a aria-label="Dulaglutide: Adverse Reaction: Abdominal Pain table link" class="lexi-table-link" data-table-id="lexi-content-dulaglutide-adverse-reaction-abdominal-pain" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-dulaglutide-adverse-reaction-abdominal-pain')">table 5</a>)</span><span class="table-link" style="display:none;">Dulaglutide: Adverse Reaction: Abdominal Pain</span>, constipation (4%), decreased appetite (5% to 9%)<span class="lexi-table-link-container"> (<a aria-label="Dulaglutide: Adverse Reaction: Decreased Appetite table link" class="lexi-table-link" data-table-id="lexi-content-dulaglutide-adverse-reaction-decreased-appetite" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-dulaglutide-adverse-reaction-decreased-appetite')">table 6</a>)</span><span class="table-link" style="display:none;">Dulaglutide: Adverse Reaction: Decreased Appetite</span>, dyspepsia (4% to 6%)<span class="lexi-table-link-container"> (<a aria-label="Dulaglutide: Adverse Reaction: Dyspepsia table link" class="lexi-table-link" data-table-id="lexi-content-dulaglutide-adverse-reaction-dyspepsia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-dulaglutide-adverse-reaction-dyspepsia')">table 7</a>)</span><span class="table-link" style="display:none;">Dulaglutide: Adverse Reaction: Dyspepsia</span>, eructation (2%), flatulence (3%), gastroesophageal reflux disease (2%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Dulaglutide: Adverse Reaction: Abdominal Pain" frame="border" id="lexi-content-dulaglutide-adverse-reaction-abdominal-pain" rules="all">
<caption style="text-align:center;">
<b>Dulaglutide: Adverse Reaction: Abdominal Pain</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Dulaglutide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Dulaglutide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1.5 mg once weekly</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">834</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">568</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.75 mg once weekly</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">836</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">568</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Dulaglutide: Adverse Reaction: Decreased Appetite" frame="border" id="lexi-content-dulaglutide-adverse-reaction-decreased-appetite" rules="all">
<caption style="text-align:center;">
<b>Dulaglutide: Adverse Reaction: Decreased Appetite</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Dulaglutide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Dulaglutide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1.5 mg once weekly</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">834</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">568</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.75 mg once weekly</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">836</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">568</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Dulaglutide: Adverse Reaction: Dyspepsia" frame="border" id="lexi-content-dulaglutide-adverse-reaction-dyspepsia" rules="all">
<caption style="text-align:center;">
<b>Dulaglutide: Adverse Reaction: Dyspepsia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Dulaglutide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Dulaglutide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1.5 mg once weekly</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">834</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">568</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.75 mg once weekly</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">836</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">568</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (children, adolescents, and adults: 2% to 6%; neutralizing: ≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction (adults: &lt;1%; children and adolescents: 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (4% to 6%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Cholecystitis (Butler 2021)<span class="lexi-table-link-container"> (<a aria-label="Cholecystitis table link" class="lexi-table-link" data-table-id="lexi-content-cholecystitis" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-cholecystitis')">table 8</a>)</span><span class="table-link" style="display:none;">Cholecystitis</span>, pancreatitis</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Cholecystitis" frame="border" id="lexi-content-cholecystitis" rules="all">
<caption style="text-align:center;">
<b>Dulaglutide: Adverse Reaction: Cholecystitis</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Dulaglutide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Serious events of acute cholecystitis</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Gastrointestinal: Increased serum amylase, increased serum lipase</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Morbilliform rash (Rzepka 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Acute pancreatitis (Gerstein 2019), biliary tract disease (He 2022), cholelithiasis (Gerstein 2019; Pratley 2018), cholestasis (He 2022), gallbladder disease (He 2022), intestinal obstruction</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis, increased liver enzymes</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (Milicevic 2016), angioedema (Milicevic 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury (Tuttle 2017), interstitial nephritis (Komala 2022)</p></div>
<div class="block coi drugH1Div" id="F25944102"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Serious hypersensitivity to dulaglutide or any component of the formulation; personal or family history of medullary thyroid carcinoma (MTC); patients with multiple endocrine neoplasia syndrome type 2 (MEN2)</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Pregnancy; breast-feeding</p></div>
<div class="block war drugH1Div" id="F26122038"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bariatric surgery:</p>
<p style="text-indent:-2em;margin-left:6em;">- Dehydration: Evaluate, correct, and maintain postsurgical fluid requirements and volume status prior to initiating therapy, and closely monitor the patient for the duration of therapy; acute and chronic kidney failure exacerbation may occur. A majority of cases occurred in patients with nausea, vomiting, diarrhea, and/or dehydration. Nausea is common and fluid intake may be more difficult after gastric bypass, sleeve gastrectomy, and gastric band (Mechanick 2020).</p>
<p style="text-indent:-2em;margin-left:6em;">- Excessive glucagon-like peptide-1 exposure: Closely monitor for efficacy and assess for signs and symptoms of pancreatitis if therapy is initiated after surgery; gastric bypass and sleeve gastrectomy (but not gastric band) significantly increase endogenous postprandial GLP-1 concentrations (Korner 2009; Peterli 2012). Administration of exogenous GLP-1 agonists may be redundant to surgery effects.</p>
<p style="text-indent:-2em;margin-left:4em;">• GI disease: Use is not recommended in patients with preexisting severe GI disease, including severe gastroparesis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Diabetes mellitus: Not recommended for first-line therapy in patients inadequately controlled on diet and exercise alone. Do not use in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis; not a substitute for insulin.</p></div>
<div class="block foc drugH1Div" id="F26111595"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Pen-injector, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Trulicity: 0.75 mg/0.5 mL (0.5 mL); 1.5 mg/0.5 mL (0.5 mL); 3 mg/0.5 mL (0.5 mL); 4.5 mg/0.5 mL (0.5 mL) [contains polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F26111593"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F26597085"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Pen-injector</b> (Trulicity Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.75 mg/0.5 mL (per 0.5 mL): $293.23</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.5 mg/0.5 mL (per 0.5 mL): $293.23</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3 mg/0.5 mL (per 0.5 mL): $293.23</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4.5 mg/0.5 mL (per 0.5 mL): $293.23</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871819"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Pen-injector, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Trulicity: 0.75 mg/0.5 mL (0.5 mL); 1.5 mg/0.5 mL (0.5 mL) [contains polysorbate 80]</p></div>
<div class="block adm drugH1Div" id="F26122245"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>SUBQ:</b> Do not inject intravenously or intramuscularly. Inject subcutaneously into the upper arm, thigh, or abdomen; when administering within the same body region, use a different injection site each week. Administer once weekly on the same day each week, without regard to meals or time of day. The day of weekly administration may be changed, as long as the last dose was administered ≥3 days before. If using concomitantly with insulin, administer as separate injections (do not mix); may inject in the same body region as insulin, but not adjacent to one another. Dulaglutide is a single-dose device that <b>does not </b>require priming before injection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30506340','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30506340','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F57549797"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">SUBQ: Dulaglutide is available as a single-dose device that does not require priming prior to use. Inject SUBQ into the upper arm, thigh, or abdomen; when administering within the same body region, use a different injection site. Administer once weekly on the same day each week, without regard to meals or time of day. The day of weekly administration may be changed if the last dose was administered ≥3 days before. Do not inject IV or IM. If using concomitantly with insulin, administer as separate injections (do not mix); may inject in the same body region as insulin, but not adjacent to one another.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed doses</i>: Missed dose should be administered as soon as possible within 3 days; resume usual schedule thereafter. If there are &lt;3 days until next scheduled dose, omit the missed dose and resume administration at the next scheduled weekly dose.</p></div>
<div class="block meg drugH1Div" id="F26123340"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2022%2F125469s046s052lbl.pdf%23page%3D27&amp;token=VO58IxOtUVnBrQPT2%2BwF4D%2F3SaI6UsTpn9t1Icmp95JDzknIMT4JUoFDfG%2FDm0aG7ci1%2Bvnq2eyQIRl3fCcp2InVU6hNaq9nvxz0gDxn7pQcIv4BpFrvILuVWsa%2B4XTx&amp;TOPIC_ID=97148" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125469s046s052lbl.pdf#page=27</a>, must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F25944038"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Diabetes mellitus, type 2, treatment:</b> As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years of age with type 2 diabetes mellitus; risk reduction of major cardiovascular events (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.</p></div>
<div class="block mst drugH1Div" id="F53013681"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Trulicity may be confused with Tanzeum [DSC], Toujeo, Tradjenta, Tresiba</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F26019377"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F26019374"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alpha-Lipoic Acid: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Androgens: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Beta1 Selective): May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Nonselective): May enhance the hypoglycemic effect of Antidiabetic Agents. Beta-Blockers (Nonselective) may diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bortezomib: May enhance the therapeutic effect of Antidiabetic Agents. Bortezomib may diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Direct Acting Antiviral Agents (HCV): May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etilefrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyperglycemia-Associated Agents: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypoglycemia-Associated Agents: Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Insulins: Glucagon-Like Peptide-1 Agonists may enhance the hypoglycemic effect of Insulins.  Management: Consider insulin dose reductions when used in combination with glucagon-like peptide-1 agonists. Monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Liraglutide: May enhance the adverse/toxic effect of Glucagon-Like Peptide-1 Agonists.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maitake: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Meglitinides: Glucagon-Like Peptide-1 Agonists may enhance the hypoglycemic effect of Meglitinides.  Management: Consider meglitinide dose reductions when used in combination with glucagon-like peptide-1 agonists, particularly when also used with basal insulin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pegvisomant: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prothionamide: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Quinolones may diminish the therapeutic effect of Agents with Blood Glucose Lowering Effects. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritodrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Semaglutide: May enhance the adverse/toxic effect of Glucagon-Like Peptide-1 Agonists.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide.  Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulfonylureas: Glucagon-Like Peptide-1 Agonists may enhance the hypoglycemic effect of Sulfonylureas.  Management: Consider sulfonylurea dose reductions when used in combination with glucagon-like peptide-1 agonists.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tirzepatide: May enhance the adverse/toxic effect of Glucagon-Like Peptide-1 Agonists.<i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F56092127"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Glucagon-like peptide-1 (GLP-1) receptor agonists are not recommended for patients with type 2 diabetes mellitus planning to become pregnant. Patients who could become pregnant should use effective contraception during therapy. Transition to a preferred therapy should be initiated prior to conception and contraception should be continued until glycemic control is achieved (ADA 2023; Alexopoulos 2019; Egan 2020)</p></div>
<div class="block pri drugH1Div" id="F26118439"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Poorly controlled diabetes during pregnancy can be associated with an increased risk of adverse maternal and fetal outcomes, including diabetic ketoacidosis, preeclampsia, spontaneous abortion, preterm delivery, delivery complications, major malformations, stillbirth, and macrosomia (ACOG 201 2018). To prevent adverse outcomes, prior to conception and throughout pregnancy, maternal blood glucose and HbA<sub>1c</sub> should be kept as close to target goals as possible but without causing significant hypoglycemia (ADA 2023; Blumer 2013).</p>
<p style="text-indent:0em;margin-top:2em;">Agents other than dulaglutide are currently recommended to treat diabetes mellitus in pregnancy (ADA 2023).</p></div>
<div class="block brc drugH1Div" id="F26118441"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if dulaglutide is present in breast milk. According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother</p></div>
<div class="block dic drugH1Div" id="F26122244"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Individualized medical nutrition therapy (MNT) based on ADA recommendations is an integral part of therapy. </p></div>
<div class="block mop drugH1Div" id="F26122247"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Plasma glucose; renal function (in patients reporting severe GI reactions); signs/symptoms of pancreatitis; worsening diabetic retinopathy (in patients with a prior history).</p>
<p style="text-indent:-2em;margin-left:2em;">HbA<sub>1c</sub>: Monitor at least twice yearly in patients who have stable glycemic control and are meeting treatment goals; monitor quarterly in patients in whom treatment goals have not been met, or with therapy change. <b>Note: </b>In patients prone to glycemic variability (eg, patients with insulin deficiency), or in patients whose HbA<sub>1c</sub> is discordant with serum glucose levels or symptoms, consider evaluating HbA<sub>1c</sub> in combination with blood glucose levels and/or a glucose management indicator (ADA 2023; KDIGO 2020).</p></div>
<div class="block rer drugH1Div" id="F26122043"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Recommendations for glycemic control in patients with diabetes:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Nonpregnant adults (AACE [Samson 2023]; ADA 2023):</i></p>
<p style="text-indent:-2em;margin-left:6em;">HbA<sub>1c</sub>: &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] HbA<sub>1c</sub> goal may be targeted based on patient-specific characteristics). <b>Note: </b>In patients using a continuous glucose monitoring system, a goal of time in range &gt;70% with time below range &lt;4% is recommended and is similar to a goal HbA<sub>1c</sub> &lt;7%.</p>
<p style="text-indent:-2em;margin-left:6em;">Preprandial capillary blood glucose: 80 to 130 mg/dL (SI: 4.4 to 7.2 mmol/L) (more or less stringent goals may be appropriate based on patient-specific characteristics).</p>
<p style="text-indent:-2em;margin-left:6em;">Peak postprandial capillary blood glucose (~1 to 2 hours after a meal): &lt;180 mg/dL (SI: &lt;10 mmol/L) (more or less stringent goals may be appropriate based on patient-specific characteristics).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Older adults (≥65 years of age) (ADA 2023):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> May consider less strict targets in patients who are using insulin and/or insulin secretagogues (sulfonylureas, meglitinides) (ES [LeRoith 2019]).</p>
<p style="text-indent:-2em;margin-left:6em;">HbA<sub>1c</sub>: &lt;7% to 7.5% (healthy); &lt;8% (complex/intermediate health). <b>Note:</b> Individualization may be appropriate based on patient and caregiver preferences and/or presence of cognitive impairment. In patients with very complex or poor health (ie, limited remaining life expectancy), consider making therapy decisions based on avoidance of hypoglycemia and symptomatic hyperglycemia rather than HbA<sub>1c</sub> level.</p>
<p style="text-indent:-2em;margin-left:6em;">Preprandial capillary blood glucose: 80 to 130 mg/dL (SI: 4.4 to 7.2 mmol/L) (healthy); 90 to 150 mg/dL (SI: 5 to 8.3 mmol/L) (complex/intermediate health); 100 to 180 mg/dL (SI: 5.6 to 10 mmol/L) (very complex/poor health).</p>
<p style="text-indent:-2em;margin-left:6em;">Bedtime capillary blood glucose: 80 to 180 mg/dL (SI: 4.4 to 10 mmol/L) (healthy); 100 to 180 mg/dL (SI: 5.6 to 10 mmol/L) (complex/intermediate health); 110 to 200 mg/dL (SI: 6.1 to 11.1 mmol/L) (very complex/poor health).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Classification of hypoglycemia (ADA 2023):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Level 1: 54 to 70 mg/dL (SI: 3 to 3.9 mmol/L); hypoglycemia alert value; initiate fast-acting carbohydrate (eg, glucose) treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">Level 2: &lt;54 mg/dL (SI: &lt;3 mmol/L); threshold for neuroglycopenic symptoms; requires immediate action.</p>
<p style="text-indent:-2em;margin-left:4em;">Level 3: Hypoglycemia associated with a severe event characterized by altered mental and/or physical status requiring assistance.</p></div>
<div class="block pha drugH1Div" id="F26122041"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Dulaglutide is an agonist of human glucagon-like peptide-1 (GLP-1) receptor and augments glucose dependent insulin secretion and slows gastric emptying.</p></div>
<div class="block phk drugH1Div" id="F26122230"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: 47% to 65%.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Central volume, mean: 3.09 L; peripheral volume, mean: 5.98 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Degradation to amino acids by protein catabolism pathways.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~5 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: 24 to 72 hours.</p></div>
<div class="block phksp drugH1Div" id="F51154000"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Dulaglutide systemic exposure increased by 20%, 28%, 14%, and 12% for mild, moderate, and severe renal impairment, and ESRD, respectively.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Dulaglutide systemic exposure decreased by 23%, 33%, and 21% for mild, moderate, and severe hepatic impairment, respectively.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F26732966"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Aplevant | Trulicity</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Trulicity</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-31087027">
<a name="31087027"></a>Alexopoulos AS, Blair R, Peters AL. Management of preexisting diabetes in pregnancy: a review. <i>JAMA</i>. 2019;321(18):1811-1819. doi:10.1001/jama.2019.4981<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/31087027/pubmed" id="31087027" target="_blank">31087027</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23010561">
<a name="23010561"></a>Alves C, Batel-Marques F, Macedo AF. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. <i>Diabetes Res Clin Pract</i>. 2012;98(2):271-284. doi:10.1016/j.diabres.2012.09.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/23010561/pubmed" id="23010561" target="_blank">23010561</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30461693">
<a name="30461693"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin No. 201: Pregestational diabetes mellitus. <i>Obstet Gynecol</i>. 2018;132(6):e228-e248. doi: 10.1097/AOG.0000000000002960.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/30461693/pubmed" id="30461693" target="_blank">30461693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29370047">
<a name="29370047"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 190: Gestational diabetes mellitus. <i>Obstet Gynecol</i>. 2018;131(2):e49-e64.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/29370047/pubmed" id="29370047" target="_blank">29370047</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADA.3">
<a name="ADA.3"></a>American Diabetes Association (ADA). Standards of care in diabetes–2023. <i>Diabetes Care</i>. 2023;46(suppl 1):S1-S291. https://diabetesjournals.org/care/issue/46/Supplement_1. Accessed January 4, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34964865">
<a name="34964865"></a>American Diabetes Association (ADA). 14. Children and Adolescents: Standards of Medical Care in Diabetes-2022. <i>Diabetes Care</i>. 2022;45(suppl 1):S208-S231. doi:10.2337/dc22-S014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/34964865/pubmed" id="34964865" target="_blank">34964865</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35658022">
<a name="35658022"></a>Arslanian SA, Hannon T, Zeitler P, et al. Once-weekly dulaglutide for the treatment of youths with type 2 diabetes. <i>N Engl J Med</i>. 2022;387(5):433-443. doi:10.1056/NEJMoa2204601<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/35658022/pubmed" id="35658022" target="_blank">35658022</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27860132">
<a name="27860132"></a>Bettge K, Kahle M, Abd El Aziz MS, Meier JJ, Nauck MA. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials. <i>Diabetes Obes Metab</i>. 2017;19(3):336-347. doi:10.1111/dom.12824<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/27860132/pubmed" id="27860132" target="_blank">27860132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20203154">
<a name="20203154"></a>Bjerre Knudsen L, Madsen LW, Andersen S, et al. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation [published correction appears in <i>Endocrinology</i>. 2012;153(2):1000. Moerch, Ulrik [added]]. <i>Endocrinology</i>. 2010;151(4):1473-1486. doi:10.1210/en.2009-1272<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/20203154/pubmed" id="20203154" target="_blank">20203154</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30558872">
<a name="30558872"></a>Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. <i>Lancet</i>. 2019;393(10167):183-198. doi:10.1016/S0140-6736(18)32218-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/30558872/pubmed" id="30558872" target="_blank">30558872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24194617">
<a name="24194617"></a>Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2013;98(11):4227-4249.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/24194617/pubmed" id="24194617" target="_blank">24194617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26120552">
<a name="26120552"></a>Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). <i>Allergo J Int</i>. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/26120552/pubmed" id="26120552" target="_blank">26120552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33594405">
<a name="33594405"></a>Butler J, Bjurstrom M, Marceau A. Possible dulaglutide-associated cholecystitis with safe continuation post cholecystectomy [published online ahead of print, 2021 Feb 17]. <i>Am J Health Syst Pharm</i>. 2021;zxab045. doi:10.1093/ajhp/zxab045<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/33594405/pubmed" id="33594405" target="_blank">33594405</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32301438">
<a name="32301438"></a>Carvallo A, Silva C, Gastaminza G, D'Amelio CM. Delayed hypersensitivity reaction to liraglutide: a case report. <i>J Investig Allergol Clin Immunol</i>. 2020;30(5):367-369. doi:10.18176/jiaci.0521<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/32301438/pubmed" id="32301438" target="_blank">32301438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33554677">
<a name="33554677"></a>Dauner DG, Farley JF. Comparing the use of individual and composite terms to evaluate adverse drug event disproportionality: a focus on glucagon-like peptide-1 receptor agonists and diabetic retinopathy [published online ahead of print, 2021 Feb 8]. <i>Expert Opin Drug Saf</i>. 2021;10.1080/14740338.2021.1887136. doi:10.1080/14740338.2021.1887136<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/33554677/pubmed" id="33554677" target="_blank">33554677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30291106">
<a name="30291106"></a>Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i>. 2018;41(12):2669-2701. doi:10.2337/dci18-0033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/30291106/pubmed" id="30291106" target="_blank">30291106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36537523">
<a name="36537523"></a>De Bock M, Codner E, Craig ME, et al. ISPAD clinical practice consensus guidelines 2022: glycemic targets and glucose monitoring for children, adolescents, and young people with diabetes. <i>Pediatr Diabetes</i>. 2022;23(8):1270-1276. doi:10.1111/pedi.13455<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/36537523/pubmed" id="36537523" target="_blank">36537523</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dungan.1">
<a name="Dungan.1"></a>Dungan K, DeSantis A. Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 23, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9682700">
<a name="9682700"></a>Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial [published correction appears in <i>Arch Ophthalmol.</i> 1998;116(11):1469]. <i>Arch Ophthalmol</i>. 1998;116(7):874-886. doi:10.1001/archopht.116.7.874<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/9682700/pubmed" id="9682700" target="_blank">9682700</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24571751">
<a name="24571751"></a>Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs--FDA and EMA assessment [published correction appears in <i>N Engl J Med</i>. 2014;370(23):2253]. <i>N Engl J Med</i>. 2014;370(9):794-797. doi:10.1056/NEJMp1314078<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/24571751/pubmed" id="24571751" target="_blank">24571751</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32736942">
<a name="32736942"></a>Egan AM, Dow ML, Vella A. A review of the pathophysiology and management of diabetes in pregnancy. <i>Mayo Clin Proc</i>. 2020;95(12):2734-2746. doi:10.1016/j.mayocp.2020.02.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/32736942/pubmed" id="32736942" target="_blank">32736942</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21334333">
<a name="21334333"></a>Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. <i>Gastroenterology</i>. 2011;141(1):150-156. doi:10.1053/j.gastro.2011.02.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/21334333/pubmed" id="21334333" target="_blank">21334333</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27478902">
<a name="27478902"></a>Faillie JL, Yu OH, Yin H, Hillaire-Buys D, Barkun A, Azoulay L. Association of bile duct and gallbladder diseases with the use of incretin-based drugs in patients with type 2 diabetes mellitus. <i>JAMA Intern Med</i>. 2016;176(10):1474-1481. doi:10.1001/jamainternmed.2016.1531<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/27478902/pubmed" id="27478902" target="_blank">27478902</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26177483">
<a name="26177483"></a>Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse effects of GLP-1 receptor agonists. <i>Rev Diabet Stud</i>. 2014;11(3-4):202-230. doi:10.1900/RDS.2014.11.202<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/26177483/pubmed" id="26177483" target="_blank">26177483</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2013">
<a name="FDA.2013"></a>Food and Drug Administration. FDA Drug Safety Communication: FDA investigating reports of possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes. Published March 14, 2013. Accessed March 26, 2021. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-investigating-reports-possible-increased-risk-pancreatitis-and-pre" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-investigating-reports-possible-increased-risk-pancreatitis-and-pre</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32022600">
<a name="32022600"></a>Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - <i>2020 executive summary</i>. <i>Endocr Pract</i>. 2020;26(1):107-139. doi:10.4158/CS-2019-0472<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/32022600/pubmed" id="32022600" target="_blank">32022600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31189511">
<a name="31189511"></a>Gerstein HC, Colhoun HM, Dagenais GR, et al; REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. <i>Lancet</i>. 2019;394(10193):121-130. doi:10.1016/S0140-6736(19)31149-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/31189511/pubmed" id="31189511" target="_blank">31189511</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30137354">
<a name="30137354"></a>Gether IM, Nexøe-Larsen C, Knop FK. New avenues in the regulation of gallbladder motility-implications for the use of glucagon-like peptide-derived drugs. <i>J Clin Endocrinol Metab</i>. 2019;104(7):2463-2472. doi:10.1210/jc.2018-01008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/30137354/pubmed" id="30137354" target="_blank">30137354</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24702687">
<a name="24702687"></a>Giorda CB, Nada E, Tartaglino B, Marafetti L, Gnavi R. A systematic review of acute pancreatitis as an adverse event of type 2 diabetes drugs: from hard facts to a balanced position. <i>Diabetes Obes Metab</i>. 2014;16(11):1041-1047. doi:10.1111/dom.12297<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/24702687/pubmed" id="24702687" target="_blank">24702687</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32621083">
<a name="32621083"></a>Guo L, Zhang B, Hou J, Zhou Z. Evaluation of characteristics of gastrointestinal adverse events with once-weekly dulaglutide treatment in Chinese patients with type 2 diabetes: a post hoc pooled analysis of two randomized trials. <i>Diabetes Ther</i>. 2020;11(8):1821-1833. doi:10.1007/s13300-020-00869-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/32621083/pubmed" id="32621083" target="_blank">32621083</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35344001">
<a name="35344001"></a>He L, Wang J, Ping F, et al. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. <i>JAMA Intern Med</i>. 2022;e220338. doi:10.1001/jamainternmed.2022.0338<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/35344001/pubmed" id="35344001" target="_blank">35344001</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27981757">
<a name="27981757"></a>Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis. <i>Diabetes Obes Metab</i>. 2017;19(4):524-536. doi:10.1111/dom.12849<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/27981757/pubmed" id="27981757" target="_blank">27981757</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32998798">
<a name="32998798"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. <i>Kidney Int</i>. 2020;98(supp 4):S1-S115. doi:10.1016/j.kint.2020.06.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/32998798/pubmed" id="32998798" target="_blank">32998798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27883260">
<a name="27883260"></a>Knapen LM, de Jong RG, Driessen JH, et al. Use of incretin agents and risk of acute and chronic pancreatitis: a population-based cohort study. <i>Diabetes Obes Metab</i>. 2017;19(3):401-411. doi:10.1111/dom.12833<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/27883260/pubmed" id="27883260" target="_blank">27883260</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36385974">
<a name="36385974"></a>Komala MG, Renthawa J. A case of dulaglutide-induced acute interstitial nephritis after many years of treatment with an alternate GLP-1 receptor agonist. <i>Clin Diabetes</i>. 2022;40(4):508-510. doi:10.2337/cd21-0142<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/36385974/pubmed" id="36385974" target="_blank">36385974</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25725635">
<a name="25725635"></a>Korkmaz H, Araz M, Alkan S, Akarsu E. Liraglutide-related cholelithiasis. <i>Aging Clin Exp Res</i>. 2015;27(5):751-753. doi:10.1007/s40520-015-0335-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/25725635/pubmed" id="25725635" target="_blank">25725635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19417773">
<a name="19417773"></a>Korner J, Inabnet W, Febres G, et al. Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass. <i>Int J Obes (Lond).</i> 2009;33(7):786-795. doi: 10.1038/ijo.2009.79.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/19417773/pubmed" id="19417773" target="_blank">19417773</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30903688">
<a name="30903688"></a>LeRoith D, Biessels GJ, Braithwaite SS, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol </i>
<i>Metab</i>. 2019;104(5):1520-1574. doi:10.1210/jc.2019-00198<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/30903688/pubmed" id="30903688" target="_blank">30903688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27633186">
<a name="27633186"></a>Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. <i>N Engl J Med</i>. 2016;375(19):1834-1844. doi:10.1056/NEJMoa1607141<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/27633186/pubmed" id="27633186" target="_blank">27633186</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27295427">
<a name="27295427"></a>Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. <i>N Engl J Med</i>. 2016;375(4):311-322. doi:10.1056/NEJMoa1603827<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/27295427/pubmed" id="27295427" target="_blank">27295427</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18829977">
<a name="18829977"></a>Marzioni M, Alpini G, Saccomanno S, et al. Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosis. <i>Gut</i>. 2009;58(7):990-997. doi:10.1136/gut.2008.150870<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/18829977/pubmed" id="18829977" target="_blank">18829977</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17631146">
<a name="17631146"></a>Marzioni M, Alpini G, Saccomanno S, et al. Glucagon-like peptide-1 and its receptor agonist exendin-4 modulate cholangiocyte adaptive response to cholestasis. <i>Gastroenterology</i>. 2007;133(1):244-255. doi:10.1053/j.gastro.2007.04.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/17631146/pubmed" id="17631146" target="_blank">17631146</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31917200">
<a name="31917200"></a>Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures -2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, The Obesity Society, American Society for Metabolic &amp; Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. <i>Surg Obes Relat Dis</i>. 2020;16(2):175-247. doi:10.1016/j.soard.2019.10.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/31917200/pubmed" id="31917200" target="_blank">31917200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26847401">
<a name="26847401"></a>Milicevic Z, Anglin G, Harper K, et al. Low incidence of anti-drug antibodies in patients with type 2 diabetes treated with once-weekly glucagon-like peptide-1 receptor agonist dulaglutide. <i>Diabetes Obes Metab</i>. 2016;18(5):533-536. doi:10.1111/dom.12640<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/26847401/pubmed" id="26847401" target="_blank">26847401</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28283565">
<a name="28283565"></a>Nauck MA, Frossard JL, Barkin JS, et al. Assessment of pancreas safety in the development program of once-weekly GLP-1 receptor agonist dulaglutide. <i>Diabetes Care</i>. 2017;40(5):647-654. doi:10.2337/dc16-0984<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/28283565/pubmed" id="28283565" target="_blank">28283565</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31399438">
<a name="31399438"></a>Nauck MA, Muus Ghorbani ML, Kreiner E, Saevereid HA, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Effects of liraglutide compared with placebo on events of acute gallbladder or biliary disease in patients with type 2 diabetes at high risk for cardiovascular events in the LEADER randomized trial. <i>Diabetes Care</i>. 2019;42(10):1912-1920. doi:10.2337/dc19-0415<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/31399438/pubmed" id="31399438" target="_blank">31399438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30350785">
<a name="30350785"></a>Ornelas C, Caiado J, Lopes A, Pereira Dos Santos MC, Pereira Barbosa M. Anaphylaxis to long-acting release exenatide. <i>J Investig Allergol Clin Immunol</i>. 2018;28(5):332-334. doi:10.18176/jiaci.0274<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/30350785/pubmed" id="30350785" target="_blank">30350785</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25439386">
<a name="25439386"></a>Pérez E, Martínez-Tadeo J, Callero A, Hernández G, Rodríguez-Plata E, García-Robaina JC. A case report of allergy to exenatide. <i>J Allergy Clin Immunol Pract</i>. 2014;2(6):822-823. doi:10.1016/j.jaip.2014.05.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/25439386/pubmed" id="25439386" target="_blank">25439386</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22354457">
<a name="22354457"></a>Peterli R, Steinert RE, Woelnerhanssen B, et al. Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial. <i>Obes Surg</i>. 2012;22(5):740-748. doi: 10.1007/s11695-012-0622-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/22354457/pubmed" id="22354457" target="_blank">22354457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26132939">
<a name="26132939"></a>Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. <i>N Engl J Med</i>. 2015;373(1):11-22. doi:10.1056/NEJMoa1411892<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/26132939/pubmed" id="26132939" target="_blank">26132939</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31806579">
<a name="31806579"></a>Pradhan R, Montastruc F, Rousseau V, Patorno E, Azoulay L. Exendin-based glucagon-like peptide-1 receptor agonists and anaphylactic reactions: a pharmacovigilance analysis. <i>Lancet Diabetes Endocrinol</i>. 2020;8(1):13-14. doi:10.1016/S2213-8587(19)30382-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/31806579/pubmed" id="31806579" target="_blank">31806579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33199417">
<a name="33199417"></a>Pratley RE, Aroda VR, Catarig AM, et al. Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 <i>post hoc</i> analyses. <i>BMJ Open</i>. 2020;10(11):e037883. Published 2020 Nov 16. doi:10.1136/bmjopen-2020-037883<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/33199417/pubmed" id="33199417" target="_blank">33199417</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29397376">
<a name="29397376"></a>Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. <i>Lancet Diabetes Endocrinol</i>. 2018;6(4):275-286. doi:10.1016/S2213-8587(18)30024-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/29397376/pubmed" id="29397376" target="_blank">29397376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer’s labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30506340">
<a name="30506340"></a>Romera I, Cebrián-Cuenca A, Álvarez-Guisasola F, Gomez-Peralta F, Reviriego J. A review of practical issues on the use of glucagon-like peptide-1 receptor agonists for the management of type 2 diabetes. <i>Diabetes Ther</i>. 2019;10(1):5-19. doi:10.1007/s13300-018-0535-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/30506340/pubmed" id="30506340" target="_blank">30506340</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33144906">
<a name="33144906"></a>Rzepka PV, Kaffenberger JA. A case of morbilliform drug eruption to dulaglutide. <i>J Clin Aesthet Dermatol</i>. 2020;13(4):13.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/33144906/pubmed" id="33144906" target="_blank">33144906</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37150579">
<a name="37150579"></a>Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm - 2023 update. <i>Endocr Pract</i>. 2023;29(5):305-340. doi:10.1016/j.eprac.2023.02.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/37150579/pubmed" id="37150579" target="_blank">37150579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36161685">
<a name="36161685"></a>Shah AS, Zeitler PS, Wong J, et al. ISPAD clinical practice consensus guidelines 2022: type 2 diabetes in children and adolescents. <i>Pediatr Diabetes</i>. 2022;23(7):872-902. doi:10.1111/pedi.13409<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/36161685/pubmed" id="36161685" target="_blank">36161685</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31296642">
<a name="31296642"></a>Shamriz O, NaserEddin A, Mosenzon O, Sviri S, Tal Y. Allergic reaction to exenatide and lixisenatide but not to liraglutide: unveiling anaphylaxis to glucagon-like peptide 1 receptor agonists. <i>Diabetes Care</i>. 2019;42(9):e141-e142. doi:10.2337/dc19-0720<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/31296642/pubmed" id="31296642" target="_blank">31296642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21975753">
<a name="21975753"></a>Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon-like peptide analogues for type 2 diabetes mellitus. <i>Cochrane Database Syst Rev</i>. 2011;2011(10):CD006423. doi:10.1002/14651858.CD006423.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/21975753/pubmed" id="21975753" target="_blank">21975753</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28533296">
<a name="28533296"></a>Simó R, Hernández C. GLP-1R as a target for the treatment of diabetic retinopathy: friend or foe? <i>Diabetes</i>. 2017;66(6):1453-1460. doi:10.2337/db16-1364<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/28533296/pubmed" id="28533296" target="_blank">28533296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23440284">
<a name="23440284"></a>Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. <i>JAMA Intern Med</i>. 2013;173(7):534-539. doi:10.1001/jamainternmed.2013.2720<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/23440284/pubmed" id="23440284" target="_blank">23440284</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Steveling.2014">
<a name="Steveling.2014"></a>Steveling EH, Winzeler B, Bircher AJ. Systemic allergic reaction to the GLP-1 receptor agonist exenatide. <i>Journal of Pharmacy Technology</i>. 2014;30(5):182-186. doi:10.1177/8755122514539462</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25375397">
<a name="25375397"></a>Sun F, Chai S, Yu K, et al. Gastrointestinal adverse events of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis. <i>Diabetes Technol Ther</i>. 2015;17(1):35-42. doi:10.1089/dia.2014.0188<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/25375397/pubmed" id="25375397" target="_blank">25375397</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25633664">
<a name="25633664"></a>Thomsen RW, Pedersen L, Møller N, Kahlert J, Beck-Nielsen H, Sørensen HT. Incretin-based therapy and risk of acute pancreatitis: a nationwide population-based case-control study. <i>Diabetes Care</i>. 2015;38(6):1089-1098. doi:10.2337/dc13-2983<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/25633664/pubmed" id="25633664" target="_blank">25633664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Trulicity.2">
<a name="Trulicity.2"></a>Trulicity (dulaglutide) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; December 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Trulicity.1">
<a name="Trulicity.1"></a>Trulicity (dulaglutide) [product monograph]. Toronto, Ontario, Canada: Eli Lilly Canada Inc; August 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27766728">
<a name="27766728"></a>Tuttle KR, McKinney TD, Davidson JA, Anglin G, Harper KD, Botros FT. Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials. <i>Diabetes Obes Metab</i>. 2017;19(3):436-441. doi:10.1111/dom.12816<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/27766728/pubmed" id="27766728" target="_blank">27766728</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24842985">
<a name="24842985"></a>Umpierrez G, Tofé Povedano S, Pérez Manghi F, Shurzinske L, Pechtner V. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). <i>Diabetes Care</i>. 2014;37(8):2168‐2176. doi:10.2337/dc13-2759<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/24842985/pubmed" id="24842985" target="_blank">24842985</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29178519">
<a name="29178519"></a>Vilsbøll T, Bain SC, Leiter LA, et al. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. <i>Diabetes Obes Metab</i>. 2018;20(4):889-897. doi:10.1111/dom.13172<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/29178519/pubmed" id="29178519" target="_blank">29178519</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25912221">
<a name="25912221"></a>Weinstock RS, Guerci B, Umpierrez G, Nauck MA, Skrivanek Z, Milicevic Z. Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study. <i>Diabetes Obes Metab</i>. 2015;17(9):849‐858. doi:10.1111/dom.12479<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/25912221/pubmed" id="25912221" target="_blank">25912221</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wexler.1">
<a name="Wexler.1"></a>Wexler DJ. Initial management of blood glucose in adults with type 2 diabetes mellitus. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 14, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23622135">
<a name="23622135"></a>Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer. <i>Gastroenterology</i>. 2013;144(6):1252-1261. doi:10.1053/j.gastro.2013.01.068<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dulaglutide-drug-information/abstract-text/23622135/pubmed" id="23622135" target="_blank">23622135</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 97148 Version 213.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
